Heaven Sent Naturals, affiliates have been acquired by Wellgenix LLC/Red Oak Capital PE
The private shareholders of Heaven Sent Naturals, Puri-Clean and Covert Labs have sold a 51.5% stake in the companies, to Red Oak Capital, a Texas-based investment company that has made a wide range of investments and focuses on profitable companies, for US$25.54 million.
Heaven Sent Naturals, Puri-Clean and Covert Labs are three related companies in the nutritional supplement industry. Their products are sold in numerous independent and health food chain stores across the USA. The shareholders had built the company from a start-up to its present size over a 15-year period and recognized the need for additional expertise to take the company through the next growth stage.
Oaklins' team in Dallas advised the seller in this transaction, which was structured to deliver cash proceeds of 66% at closing and the remaining 33% to be paid annually over the next 5 years.
Talk to the deal team
Bryan Livingston
Oaklins Capital Alliance
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more